RXRX Stock - Recursion Pharmaceuticals, Inc.
Unlock GoAI Insights for RXRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $58.84M | $43.88M | $39.68M | $10.00M | $3.41M |
| Gross Profit | $13.60M | $1.29M | $-8,594,000 | $10.00M | $3.41M |
| Gross Margin | 23.1% | 2.9% | -21.7% | 100.0% | 100.0% |
| Operating Income | $-479,004,000 | $-350,060,000 | $-245,727,000 | $-182,775,000 | $-84,615,000 |
| Net Income | $-463,661,000 | $-328,066,000 | $-239,476,000 | $-186,479,000 | $-87,006,000 |
| Net Margin | -788.0% | -747.7% | -603.5% | -1864.8% | -2549.3% |
| EPS | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit WebsiteEarnings History & Surprises
RXRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.38 | $-0.36 | +5.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-0.44 | $-0.50 | -13.6% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.44 | $-0.53 | -20.5% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.35 | $-0.40 | -14.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.43 | $-0.39 | +9.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.46 | $-0.40 | +13.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.38 | $-0.38 | 0.0% | = MET |
Q2 2023 | May 8, 2023 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2023 | Feb 27, 2023 | $-0.15 | $-0.31 | -106.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.36 | $-0.35 | +2.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.51 | $-0.33 | -164.7% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-0.30 | $-0.38 | -26.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.28 | $-0.28 | 0.0% | = MET |
Q3 2021 | Aug 13, 2021 | $-0.23 | $-0.31 | -34.8% | ✗ MISS |
Latest News
Frequently Asked Questions about RXRX
What is RXRX's current stock price?
What is the analyst price target for RXRX?
What sector is Recursion Pharmaceuticals, Inc. in?
What is RXRX's market cap?
Does RXRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RXRX for comparison